Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spinal muscular atrophy: molecular pathophysiology.

N H Gendron1, A E MacKenzie

  • 1Children's Hospital of Eastern Ontario Research Institute, Solange Gauthier Karsh Laboratory, Ottawa, Canada. nathalie@mgcheo.med

Current Opinion in Neurology
|May 5, 1999
PubMed
Summary

Spinal muscular atrophy (SMA) is a genetic disease causing muscle weakness. Gene research offers hope for new treatments like gene therapy for this rare disorder.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GPR35 as a Novel Therapeutic Target.

Frontiers in endocrinology·2012
Same author

A two-site ELISA can quantify upregulation of SMN protein by drugs for spinal muscular atrophy.

Neurology·2008
Same author

Predictors of quality of life following stroke.

Disability and rehabilitation·2002
Same author

Neuronal apoptosis inhibitory protein expression after traumatic brain injury in the mouse.

Journal of neurotrauma·2002
Same author

Tudor reign.

Nature structural biology·2001
Same author

Needs of Chinese families of critically ill patients.

Western journal of nursing research·2000

Area of Science:

  • Genetics
  • Neurology
  • Molecular Biology

Background:

  • Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder.
  • It is characterized by motor neuron loss, leading to muscle atrophy and weakness.
  • Reduced levels of survival motor neuron (SMN) protein, caused by SMN1 gene defects, are implicated in SMA pathogenesis.

Purpose of the Study:

  • To explain the genetic basis of Spinal Muscular Atrophy.
  • To discuss the role of SMN1 gene mutations and SMN2 gene in SMA.
  • To explore the potential of gene therapy and gene activation for SMA treatment.

Main Methods:

  • Review of genetic studies on Spinal Muscular Atrophy.
  • Analysis of the function of SMN1 and SMN2 genes.

Related Experiment Videos

  • Discussion of molecular mechanisms underlying SMA.

    • Main Results:

    • SMN1 gene deletion or mutation leads to reduced SMN protein levels.
    • SMN protein deficiency interferes with spliceosome assembly.
    • The SMN2 gene influences clinical severity in SMA patients.

    Conclusions:

    • SMN1 is the primary causative gene for Spinal Muscular Atrophy.
    • Modifying genes, including SMN2, contribute to SMA variability.
    • Gene therapy and in-vivo gene activation are promising therapeutic strategies for SMA.